



LJMU Research Online

Bibollet-Ruche, F, Russell, RM, Liu, W, Stewart-Jones, GBE, Sherrill-Mix, S, Li, Y, Learn, GH, Smith, AG, Gondim, MVP, Plenderleith, LJ, Decker, JM, Easlick, JL, Wetzel, KS, Collman, RG, Ding, S, Finzi, A, Ayouba, A, Peeters, M, Leendertz, FH, van Schijndel, J, Goedmakers, A, Ton, E, Boesch, C, Kuehl, H, Arandjelovic, M, Dieguez, P, Murai, M, Colin, C, Koops, K, Speede, S, Gonder, MK, Muller, MN, Sanz, CM, Morgan, DB, Atencia, R, Cox, D, Piel, AK, Stewart, FA, Ndjango, J-BN, Mjungu, D, Lonsdorf, EV, Pusey, AE, Kwong, PD, Sharp, PM, Shaw, GM and Hahn, BH

CD4 receptor diversity in chimpanzees protects against SIV infection

<http://researchonline.ljmu.ac.uk/id/eprint/10006/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Bibollet-Ruche, F, Russell, RM, Liu, W, Stewart-Jones, GBE, Sherrill-Mix, S, Li, Y, Learn, GH, Smith, AG, Gondim, MVP, Plenderleith, LJ, Decker, JM, Easlick, JL, Wetzel, KS, Collman, RG, Ding, S, Finzi, A, Ayouba, A, Peeters, M, Leendertz, FH, van Schiindel, J, Goedmakers, A, Ton, E, Boesch, C.

LJMU has developed [LJMU Research Online](http://researchonline.ljmu.ac.uk/) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

<http://researchonline.ljmu.ac.uk/>

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

CD4 receptor diversity in chimpanzees protects against SIV infection

Frederic Bibollet-Ruche^{a,1}, Ronnie M. Russell^{a,b,1}, Weimin Liu^a, Guillaume B. E. Stewart-Jones^c, Scott Sherrill-Mix^{a,b}, Yingying Li^a, Gerald H. Learn^a, Andrew G. Smith^a, Marcos V. P. Gondim^a, Lindsey J. Plenderleith^{d,e}, Julie M. Decker^f, Juliet L. Easlick^g, Katherine S. Wetzel^b, Ronald G. Collman^{a,b}, Shilei Ding^{h,i}, Andrés Finzi^{h,i}, Ahidjo Ayoub^a, Martine Peeters^j, Fabian H. Leendertz^k, Joost van Schijndel^{l,m}, Annemarie Goedmakers^m, Els Ton^m, Christophe Boesch^l, Hjalmar Kuehl^l, Mimi Arandjelovic^l, Paula Dieguez^l, Mizuki Murai^l, Christelle Colinⁿ, Kathelijne Koops^o, Sheri Speede^p, Mary K. Gonder^q, Martin N. Muller^r, Crickette M. Sanz^{s,t}, David B. Morgan^{t,u}, Rebecca Atencia^v, Debby Cox^{v,w}, Alex K. Piel^x, Fiona A. Stewart^x, Jean-Bosco N. Ndjango^y, Deus Mjungu^z, Elizabeth V. Lonsdorf^{aa}, Anne E. Pusey^{bb}, Peter D. Kwong^c, Paul M. Sharp^{d,e}, George M. Shaw^{a,b}, and Beatrice H. Hahn^{a,b,2}

^aDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104; ^bDepartment of Microbiology, University of Pennsylvania, Philadelphia, PA 19104; ^cVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; ^dInstitute of Evolutionary Biology, University of Edinburgh, EH9 3FL Edinburgh, United Kingdom; ^eCentre for Immunity, Infection and Evolution, University of Edinburgh, EH9 3FL Edinburgh, United Kingdom; ^fDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294; ^gDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294; ^hDépartement de Microbiologie, Infectiologie et Immunologie, Centre de Recherche du Centre Hospitalier de L'Université de Montréal, Montréal, QC H2X0A9, Canada; ⁱDépartement de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X0A9, Canada; ^jRecherche Translationnelle Appliquée au VIH et aux Maladies Infectieuses, Institut de Recherche pour le Développement, University of Montpellier, INSERM, 34090 Montpellier, France; ^kResearch Group Epidemiology of Highly Pathogenic Microorganisms, Robert Koch Institute, 13353 Berlin, Germany; ^lDepartment of Primatology, Max Planck Institute for Evolutionary Anthropology, 04103 Leipzig, Germany; ^mChimbo Foundation, 1011 PW Amsterdam, The Netherlands; ⁿProjet Primates France, Centre de Conservation pour Chimpanzés, BP 36 Faranah, Republic of Guinea; ^oDepartment of Anthropology, University of Zurich, CH-8006 Zurich, Switzerland; ^pSanaga-Yong Chimpanzee Rescue Center, In Defense of Animals-Africa, Portland, OR 97204; ^qDepartment of Biology, Drexel University, Philadelphia, PA 19104; ^rDepartment of Anthropology, University of New Mexico, Albuquerque, NM 87131; ^sDepartment of Anthropology, Washington University in St. Louis, St. Louis, MO 63130; ^tCongo Program, Wildlife Conservation Society, BP 14537 Brazzaville, Republic of the Congo; ^uLester E. Fisher Center for the Study and Conservation of Apes, Lincoln Park Zoo, Chicago, IL 60614; ^vTchimpounga Chimpanzee Rehabilitation Center, The Jane Goodall Institute-Congo, BP 1206 Pointe Noire, Republic of Congo; ^wAfrica Programs, The Jane Goodall Institute, Vienna, VA 22182; ^xSchool of Natural Sciences and Psychology, Liverpool John Moores University, L3 3AF Liverpool, United Kingdom; ^yDepartment of Ecology and Management of Plant and Animal Resources, Faculty of Sciences, University of Kisangani, BP 2012 Kisangani, Democratic Republic of the Congo; ^zGombe Stream Research Centre, The Jane Goodall Institute, Kigoma, Tanzania; ^{aa}Department of Psychology, Franklin and Marshall College, Lancaster, PA 17604; and ^{bb}Department of Evolutionary Anthropology, Duke University, Durham, NC 27708

Contributed by Beatrice H. Hahn, December 26, 2018 (sent for review December 13, 2018; reviewed by Facundo Batista and Jeremy Luban)

Human and simian immunodeficiency viruses (HIV/SIVs) use CD4 as the primary receptor to enter target cells. Here, we show that the chimpanzee CD4 is highly polymorphic, with nine coding variants present in wild populations, and that this diversity interferes with SIV envelope (Env)-CD4 interactions. Testing the replication fitness of SIVcpz strains in CD4⁺ T cells from captive chimpanzees, we found that certain viruses were unable to infect cells from certain hosts. These differences were recapitulated in CD4 transfection assays, which revealed a strong association between CD4 genotypes and SIVcpz infection phenotypes. The most striking differences were observed for three substitutions (Q25R, Q40R, and P68T), with P68T generating a second N-linked glycosylation site (N66) in addition to an invariant N32 encoded by all chimpanzee CD4 alleles. In silico modeling and site-directed mutagenesis identified charged residues at the CD4-Env interface and clashes between CD4- and Env-encoded glycans as mechanisms of inhibition. CD4 polymorphisms also reduced Env-mediated cell entry of monkey SIVs, which was dependent on at least one D1 domain glycan. CD4 allele frequencies varied among wild chimpanzees, with high diversity in all but the western subspecies, which appeared to have undergone a selective sweep. One allele was associated with lower SIVcpz prevalence rates in the wild. These results indicate that substitutions in the D1 domain of the chimpanzee CD4 can prevent SIV cell entry. Although some SIVcpz strains have adapted to utilize these variants, CD4 diversity is maintained, protecting chimpanzees against infection with SIVcpz and other SIVs to which they are exposed.

CD4 | SIV | chimpanzee | envelope glycoprotein | glycan restriction

Simian immunodeficiency viruses (SIVs) represent a diverse group of lentiviruses that infect over 40 primate species in sub-Saharan Africa (1). Most of these comprise Old World monkeys (Cercopithecidae), but chimpanzees (*Pan troglodytes*) and western gorillas (*Gorilla gorilla*) also harbor SIV (2–5). Studies of antiviral restriction factors, such as APOBEC, tetherin,

Significance

CD4 is known to have evolved rapidly in primates, but the reason for this diversification is unknown. Here, we show that polymorphisms in the simian immunodeficiency virus (SIV) envelope (Env) binding domain of the CD4 receptor modulate the susceptibility of chimpanzee CD4⁺ T cells to SIV infection by interfering with Env-CD4 interactions required for viral entry. Both amino acid substitutions and N-linked glycosylation sites in the D1 domain blocked Env-mediated entry of a number of SIVs, including viruses that infect primates on which chimpanzees prey. These data identify steric hindrance between cell entry receptor-encoded and virus surface protein-encoded glycans as a mechanism of antiviral protection and suggest that selection pressures by primate lentiviruses, both extant and extinct, have shaped the evolution of chimpanzee CD4.

Author contributions: F.B.-R., R.M.R., G.M.S., and B.H.H. designed research; F.B.-R., R.M.R., W.L., G.B.E.S.-J., Y.L., A.G.S., M.V.P.G., J.M.D., J.L.E., K.S.W., R.G.C., S.D., A.F., A.A., and M.P. performed research; K.S.W., R.G.C., M.P., F.H.L., J.v.S., A.G., E.T., C.B., H.K., M.A., P.D., M.M., C.C., K.K., S.S., M.K.G., M.N.M., C.M.S., D.B.M., R.A., D.C., A.K.P., F.A.S., J.-B.N.N., D.M., E.V.L., and A.E.P. contributed new reagents/analytic tools; F.B.-R., R.M.R., W.L., G.B.E.S.-J., S.S.-M., G.H.L., L.J.P., P.D.K., and P.M.S. analyzed data; and F.B.-R., R.M.R., P.M.S., G.M.S., and B.H.H. wrote the paper.

Reviewers: F.B., Massachusetts General Hospital; and J.L., University of Massachusetts Medical School.

The authors declare no conflict of interest.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: Chimpanzee mitochondrial D-loop, CD4 coding, and CD4 exons 2 and 3 sequences have been deposited in the GenBank database (accession nos. [MK178722-MK178852](https://doi.org/10.26434/chemrxiv-2019-01), [MK208828-MK208836](https://doi.org/10.26434/chemrxiv-2019-01), and [MK208839-MK208845](https://doi.org/10.26434/chemrxiv-2019-01), respectively). Analysis code is archived on Zenodo (doi: [https://zenodo.org/record/2527032.XDAqz9lZblU](https://doi.org/10.5281/zenodo.2527032)).

¹F.B.-R. and R.M.R. contributed equally to this work.

²To whom correspondence should be addressed. Email: bhahn@penmedicine.upenn.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1821197116/-DCSupplemental.

TRIM5, and SAMHD1, have suggested that SIVs have been infecting primates for millions of years (6–8), which is consistent with their complex evolutionary history characterized by virus–host coevolution, cross-species transmission, recombination, and lineage extinction (9–13). SIVs can be highly pathogenic in both primate and human hosts (14, 15), with SIVcpz from chimpanzee having generated HIV type 1 (HIV-1), the cause of the AIDS pandemic (16). Primate hosts with more longstanding SIV infections, such as African green monkeys (*Chlorocebus* genus) and sooty mangabeys (*Cercocebus atys*), have evolved mechanisms that shield them from the pathogenic effects of their SIV strains (15, 17–19). However, such protective barriers are absent when SIVs invade new, nonadapted hosts.

Chimpanzees (*P. troglodytes*) are comprised of four geographically distinct subspecies, including western (*Pan troglodytes verus*), Nigeria-Cameroonian (*Pan troglodytes ellioti*), central (*Pan troglodytes troglodytes*), and eastern (*Pan troglodytes schweinfurthii*) chimpanzees (SI Appendix, Fig. S1). Only the central and eastern subspecies are SIVcpz-infected (16, 20–22), suggesting that this virus was introduced after the divergence and geographic separation of the other two subspecies. Analysis of the SIVcpz genome has shown that it is mosaic, indicating acquisition by cross-species transmission and recombination of SIVs infecting monkey species on which chimpanzees prey (10). Central chimpanzees subsequently transmitted SIVcpzPtt to humans, generating both pandemic (group M) and nonpandemic (group N) HIV-1, as well as to western lowland gorillas (*Gorilla gorilla gorilla*), generating SIVgor (5, 22, 23). Western gorillas, in turn, transmitted SIVgor to humans, generating HIV-1 groups O and P (24, 25). Although the impact of SIVgor infection on the health and longevity of wild gorillas is not known, SIVcpz is pathogenic in its natural host (26, 27). Infected chimpanzees in Gombe National Park, Tanzania, have a higher mortality than uninfected chimpanzees (27, 28). In addition, infected females have lower birth rates and a higher infant mortality (27, 28). Even members of chimpanzee subspecies that do not naturally harbor SIVcpz are susceptible to infection and disease. Examples include the transmission of SIVcpzPtt from a central chimpanzee to a Nigeria-Cameroonian cage mate (29) and the experimental infection of a western chimpanzee with SIVcpzPts that resulted in high titer viremia, CD4 T cell depletion, and clinical AIDS requiring antiretroviral therapy (30).

Despite their genetic diversity, all SIVcpz strains characterized to date share an identical genome structure (10). This indicates that SIVcpz arose only once, which may seem surprising, given that chimpanzees are routinely exposed to a plethora of SIVs through their hunting behavior (31). The absence of additional SIV infections has been attributed to the antiviral activity of innate restriction and viral dependency factors, such as proteins of the APOBEC3 family and the nucleoporin RanBP2, which represent potent barriers to cross-species transmission (7, 32). However, these host factors cannot explain the uneven distribution of SIVcpz in wild chimpanzee populations, which is characterized by high prevalence rates in some communities and rare or absent infection in others (4, 21, 22). It is also unclear why Nigeria-Cameroonian chimpanzees, which are susceptible to infection (29), do not harbor SIVcpz. Although separated from SIVcpz-infected *P. t. troglodytes* apes by the Sanaga River, this boundary is not absolute (22, 33). Chimpanzees thus appear to have evolved additional protective mechanisms that limit their infection with SIVcpz and other SIVs.

Unlike lentiviruses infecting other mammals, SIVs gain entry into target cells by using CD4, which is expressed on a variety of immune cells, including helper T cells, macrophages, and dendritic cells. Helper T cells require CD4 to stimulate the interaction of their T cell receptor (TCR) with major histocompatibility complex class II (MHC II) molecules expressed on antigen-presenting cells. As part of the TCR complex, the most outward domain of CD4 (D1 domain) interacts with a nonpolymorphic region on MHC II (34–36). Interestingly, this same D1 domain is also the region that

is bound by the envelope (Env) glycoprotein of primate lentiviruses (37, 38). Several groups have compared the amino acid sequences of CD4 between different primate species and found that residues in the D1 domain are under positive selection (39, 40). Moreover, African green monkeys, sooty mangabeys, and chimpanzees are known to encode polymorphic CD4 receptors (41–43). It has thus been suggested that the CD4 diversification in the primate lineage is the result of SIV-driven selection (40); however, evidence for this hypothesis has been lacking. Here, we show that naturally occurring amino acid substitutions in the D1 domain of the chimpanzee CD4 not only curb SIVcpz infection, but potentially also guard against cross-species transmission of SIVs infecting monkeys that are hunted by chimpanzees.

Results

Chimpanzee CD4⁺ T Cell Cultures Differ in Their Susceptibility to SIVcpz Infection. Generating infectious molecular clones (IMCs) of SIVcpz, we previously noted that some viruses that replicated efficiently in human CD4⁺ T cells were unable to infect chimpanzee CD4⁺ T cells (44). To examine this surprising phenotype, we obtained leftover blood samples from 28 healthy chimpanzees housed at US primate centers and infected their CD4⁺ T cells with a panel of eight chimpanzee viruses representing both SIVcpzPtt (MT145, EK505, MB897, LB715, and GAB2) and SIVcpzPts (BF1167, TAN2, and TAN13) strains (21, 44–47). SIVcpz IMCs were transfected, normalized based on infectivity in a permissive cell line (TZM-bl), and used to infect CD4⁺ T cells at a multiplicity of infection of 0.1 (Fig. 1). As observed previously (21, 44, 47), all SIVcpz strains replicated efficiently in human CD4⁺ T cells (Fig. 1A). However, their ability to establish a productive infection in chimpanzee CD4⁺ T cells varied considerably. Of the 28 chimpanzees tested, only 9 supported the replication of all, or nearly all, SIVcpz strains (e.g., Melissa in Fig. 1B and D) while 18 others were refractory to six of the eight viruses (e.g., Dona in Fig. 1C and D). Although not all viruses could be tested in cells from all animals, 15 chimpanzees supported replication of only TAN2 and MT145 while 3 others supported replication of only EK505 and MT145 (Fig. 1D). Cells from one chimpanzee (Chip) supported the replication of MT145, EK505, GAB2, and LB715, but not MB897, BF1167, and TAN2 (Fig. 1D). These infectivity patterns were reproducible in all instances where repeat blood samples from the same individuals were available (SI Appendix, Table S1). Only a single SIVcpz strain, MT145, was able to replicate in CD4⁺ T cells from all 28 chimpanzees (Fig. 1D). These results showed that, unlike human CD4⁺ T cells, chimpanzee CD4⁺ T cells were refractory to a subset of viruses, with susceptibility influenced by both host- and virus-specific determinants.

Refractory CD4⁺ T Cells Exhibit an Entry Block. To determine at which step in the life cycle SIVcpz was blocked, we generated a replication-competent SIVcpz reporter virus by inserting an enhanced green fluorescent protein (eGFP) gene between the *env* and *nef* genes of the SIVcpz MB897 molecular clone (SI Appendix, Fig. S2A). A transfection-derived stock of this reporter virus was then used to infect activated human and chimpanzee CD4⁺ T cells. Consistent with results obtained for the WT MB897 strain (Fig. 1D), eGFP expression was detected in CD4⁺ T cells from humans and susceptible chimpanzees, but not in CD4⁺ T cells from refractory chimpanzees (SI Appendix, Fig. S2B). However, complementation of the MB897 reporter virus with the vesicular stomatitis virus G protein (VSV-G) resulted in productive infection of all cultures (SI Appendix, Fig. S2B). These data indicated that SIVcpz was inhibited at the level of cell entry.

CD4 Polymorphisms Govern the Susceptibility of CD4⁺ T Cells to SIVcpz Infection. In addition to CD4, SIVcpz utilizes the chemokine receptor CCR5 to infect target cells (21, 44). Since the VSV-G complementation studies suggested a block at the receptor and/or coreceptor level, we sequenced the *CD4* and




Fig. 1. Chimpanzee CD4⁺ T cells differ in their susceptibility to SIVcpz infection. (A–C) The replication potential of eight SIVcpz strains is shown in activated CD4⁺ T cells from one human (A) and two chimpanzees (B and C). Viral replication was monitored in culture supernatants by determining reverse transcriptase (RT) activity (ng/mL). (D) CD4⁺ T cells from 28 captive chimpanzees (columns) were infected with different strains of SIVcpz (rows) and monitored for viral replication. The chimpanzee-adapted HIV-1 SG3 strain was used for positive control (*SI Appendix, SI Materials and Methods*). RT activity at day 13 was used to classify each culture as supporting robust (>5 ng/mL RT, dark circles), weak (1 to 5 ng/mL RT, grey circles), or no (<1 ng/mL RT, white circles) viral replication (*SI Appendix, Table S1*). Replication results are shown in relation to the respective chimpanzee CD4 genotype, with the position of polymorphic amino acid residues highlighted. (E) Protein sequences of five chimpanzee CD4 variants shown in comparison with human CD4 (residues are numbered according to their position in the mature CD4 protein). Extracellular (D1 to D4), transmembrane (TM), and intracytoplasmic domains of the protein are indicated relative to their coding exons (highlighted by alternating black and blue text), with the D1 domain underlined in red. Dots indicate amino acid identity to the human sequence, with the polymorphic sites in the D1 domain highlighted in red. Conserved and polymorphic potential N-linked glycosylation sites (PNGSs) are shaded in gray and red, respectively.

CCR5 genes of all 28 chimpanzees. In contrast to the *CCR5* gene, which comprises a single coding exon, the *CD4* gene is expressed from nine exons, some of which have been reported to be polymorphic (42). Since previous studies did not ensure linkage of variable sites and failed to guard against PCR artifacts (42), we extracted RNA from chimpanzee CD4⁺ T cells and used limiting dilution RT-PCR to amplify single CD4 transcripts (48). These analyses showed that none of the 28 chimpanzees exhibited mutations in their *CCR5* gene. However, analysis of

their *CD4* sequences revealed several single nucleotide polymorphisms (SNPs), four of which changed the amino acid sequence of the mature CD4 protein (*SI Appendix, Fig. S3A*). These nonsynonymous SNPs caused substitutions at positions 40 (Q/R), 52 (N/K), 55 (V/I), and 68 (P/T), the combination of which resulted in five CD4 variants that differed solely in their D1 domain (Fig. 1E). Importantly, the P68T substitution created a potential N-linked glycosylation site (PNGS) at position 66, in addition to the invariant PNGS present at position 32 present in

all chimpanzee *CD4* alleles (Fig. 1E). Based on the amino acids present at positions 40, 52, 55, and 68, we designated the chimpanzee *CD4* alleles QNIP, QNVP, QNVT, RNVP, and RKVT, respectively (SI Appendix, Table S2); the latter two had not previously been described (42).

Comparing the *CD4* allelic diversity between permissive and refractory cultures, we found a remarkable association between the *CD4* genotype and SIVcpz infection phenotype (Fig. 1D). *CD4*⁺ T cells from four chimpanzees, which were heterozygous for the QNVT and QNVP alleles, supported replication of all eight SIVcpz strains while *CD4*⁺ T cells from four other chimpanzees, which were heterozygous for QNVT and QNIP alleles, supported the same set of viruses, except for GAB2. In contrast, chimpanzees homozygous for the QNVT allele supported infection of only two of the eight SIVcpz strains. This was also true for chimpanzees heterozygous for the QNVT and RKVT alleles except this genotype inhibited TAN2 instead of EK505. In general, *CD4*⁺ T cells from chimpanzees with the same *CD4* genotype were susceptible to infection by the same set of viruses while even a single amino acid substitution in one of the two *CD4* alleles changed the number or types of viruses that were able to replicate (Fig. 1D).

Chimpanzee Subspecies Differ in Their *CD4* Diversity. The finding of new *CD4* alleles among captive chimpanzees suggested that additional variants might exist in wild populations. To determine the full extent of *CD4* diversity, we thus made use of our extensive collection of blood and fecal samples obtained previously from wild and sanctuary chimpanzees for molecular epidemiological studies of SIVcpz and ape *Plasmodium* infections (22, 49, 50). Samples were selected based on their geographic and subspecies origin, SIVcpz infection status, and individual information (SI Appendix, Table S3). Since the chimpanzee *CD4* gene spans a 19-Kb region on chromosome 12, with a large intron (13.7 Kb) separating exons 2 and 3, we were unable to amplify the entire *CD4* coding region from a single DNA template. However, since all *CD4* polymorphisms were located in the D1 domain, we amplified exon 2 (247 bp) and exon 3 (222 bp) separately, sequencing their respective amplicons without fragmentation to maintain linkage between polymorphic sites. Homozygous loci were amplified up to eight times to exclude allelic dropout. Using this approach, we *CD4* genotyped 60 *P. t. verus*, 41 *P. t. ellioti*, 246 *P. t. troglodytes*, and 197 *P. t. schweinfurthii* apes that were sampled at 58 sites throughout their range (SI Appendix, Fig. S1). Although exons 2 and 3 were sequenced separately, we were able to infer 13 different D1 domain haplotypes from individuals who were homozygous for one of the two exons (SI Appendix, Fig. S3B). These haplotypes contained one synonymous SNP (g/a) at the second nucleotide of exon 2 (nucleotide position 51 of the *CD4* coding sequence) and five nonsynonymous SNPs, which resulted in amino acid substitutions at positions 25, 40, 52, 55, and 68 of the mature *CD4* protein. Comparison of these to *CD4* sequences from other ape species identified the (g)QQNVP allele as the ancestral state, which appeared to have diversified both by point mutations and recombination, including within exons 2 and 3 (SI Appendix, Fig. S3B). Thus, in contrast to the human *CD4*, for which the most common D1 variant occurs at a frequency of only 6.6×10^{-5} (SI Appendix, SI Materials and Methods), the chimpanzee *CD4* is highly polymorphic in this domain, with nine coding variants of *CD4* identified in wild populations (Fig. 2A).

Chimpanzees are believed to have originated in west central Africa where they initially split into two lineages when the ancestor of *P. t. verus* and *P. t. ellioti* diverged from the ancestor of *P. t. troglodytes* and *P. t. schweinfurthii* (51). Given these relationships and the fact that only central and eastern chimpanzees are SIVcpz-infected, we expected *P. t. verus* and *P. t. ellioti* to exhibit similar levels of *CD4* diversity and to differ from *P. t. troglodytes* and *P. t. schweinfurthii* both in the number and distribution of *CD4* alleles. However, this was not the case. Instead, we found *P. t. ellioti* and *P. t. troglodytes* to be most similar, with

exon 2 QQ and QR alleles and exon 3 NVP, NIP, and KVT alleles present at comparable frequencies in both subspecies. Although *P. t. troglodytes* exhibited two additional exon 3 alleles (NVT and KVP), both were extremely rare and may thus have been missed in the less extensively sampled *P. t. ellioti* subspecies. *P. t. schweinfurthii* also encoded multiple *CD4* alleles, but their frequencies differed markedly from those in *P. t. troglodytes* and *P. t. ellioti*. For example, using the *CD4* exon 3 haplotype frequencies, G_{ST} (a measure of population differentiation) (52) between *P. t. troglodytes* and *P. t. schweinfurthii* was 0.31, compared with only 0.11 between *P. t. troglodytes* and *P. t. ellioti*. Moreover, none of the eastern chimpanzees encoded the R40 allele, but instead some encoded an R25 allele, which was found only in chimpanzees living in Gombe National Park in Tanzania (SI Appendix, Table S3). The most surprising finding was that *P. t. verus* apes did not exhibit any *CD4* polymorphisms. Although 60 individuals were sampled at five different locations throughout West Africa (SI Appendix, Fig. S1), every single one was homozygous for the (a)QQNVT allele (Fig. 2B). Given the scarcity of the exon 3 NVT allele in the other three subspecies, the predominance of this allele is unlikely the result of a founder effect. Instead, *P. t. verus* apes appear to have undergone a selective sweep, possibly in response to an SIV-like pathogen that has since gone extinct. Taken together, these findings suggest that the various *CD4* polymorphisms evolved before the introduction of present-day SIVcpz and likely already existed in the chimpanzee ancestor.

***CD4* Polymorphisms Inhibit SIVcpz Infection.** To examine the interaction of the nine *CD4* alleles with individual SIVcpz Envs, we developed a single round infection assay by transfecting 293T cells with vectors expressing human and chimpanzee *CD4* alleles, along with the chimpanzee CCR5 gene, and then infecting these cells with pseudotyped viruses carrying the Envs of different SIVcpz strains. As the pseudotyping backbone, we used an *env*-deficient version of the GFP-expressing MB897 reporter virus, which allowed the use of flow cytometry to identify infected (GFP-expressing) cells




Fig. 2. Allelic diversity of *CD4* in chimpanzees. (A) *CD4* coding variants identified in wild chimpanzee populations. D1 domain alleles are compared with the human *CD4*, with partial exons 2 and 3 derived sequences color-coded. Only the polymorphic region is shown (see Fig. 1E for an alignment of full-length *CD4* coding sequences). Dots indicate identical amino acids while arrows highlight polymorphic sites, with their position in the mature *CD4* protein indicated. (B) Frequencies of exon 2 and 3 alleles among members of the four chimpanzee subspecies. Exon 2 includes polymorphic amino acids at positions 25 (Q/R) and 40 (Q/R) while exon 3 includes polymorphic amino acids at positions 52 (N/K), 55 (I/V), and 68 (P/T). The number of chimpanzees sequenced for each subspecies is indicated.

(*SI Appendix, Fig. S4*). The results of these studies largely recapitulated the replication data obtained in primary CD4⁺ T cells (Figs. 1 and 3). First, most SIVcpz Envs used the human CD4 more efficiently than any of the chimpanzee CD4 alleles (Fig. 3), consistent with the universal susceptibility of human CD4⁺ T cells to SIVcpz infection. Second, the Env of the promiscuous MT145 strain utilized all CD4 alleles while cell entry of the more restricted MB897 Env was markedly reduced in QQNVT-expressing cells and nearly completely blocked in QRNV- and QRKVT-expressing cells (Fig. 3). Analysis of new CD4 alleles from wild chimpanzees extended these results and identified R25, R40, and T68 as the most inhibiting substitutions. All chimpanzee CD4 alleles contain a PNGS at residue 32, not found in human CD4, while those with a threonine at position 68 (T68) contain two PNGSs. Interestingly, chimpanzee CD4 alleles with a P at position 68 (P68) reduced the infectivity of all SIVcpz Envs, compared with the human CD4, while chimpanzee CD4 alleles that encoded a threonine at position 68 (T68) reduced their infectivity even further (*SI Appendix, Fig. S5A*). This inhibition was not dependent on the baseline infectivity of these SIVcpz Envs, nor on the allelic context of the P68T substitution (*SI Appendix, Fig. S6A*), suggesting that the presence of two glycans in the D1 domain is more protective than the presence of only one.

In contrast to the changes in PNGS numbers, other amino acid substitutions in the D1 domain affected only a subset of SIVcpz Envs. For example, the substitution of a glutamine to an arginine at position 25 (Q25R) reduced cell entry of BF1167, TAN2, and TAN13 by up to 18-fold but had little effect on the remaining SIVcpz Envs, except for GAB2, whose infectivity was slightly enhanced (*SI Appendix, Figs. S5B and S6B*). Similarly, the substitution of a glutamine to an arginine at position 40 (Q40R) reduced MB897, BF1167, TAN2, and TAN13 cell entry more than 100-fold but did not appear to inhibit any of the other SIVcpz Envs (*SI Appendix, Figs. S5C and S6C*). The change from an asparagine to a lysine at position 52 (N52K) inhibited all SIVcpz Envs modestly in the context of the QQNVP allele but had a slight enhancing effect in the context of the QQNVT allele (*SI Appendix, Figs. S5D and S6D*). Finally, the change from a valine to an isoleucine at position 55 (V55I) had no detectable effect in the context of both the QQNVP and QRNV alleles (*SI Appendix, Figs. S5E and S6E*). Thus, while CD4 polymorphisms were able to block SIVcpz cell entry, the inhibitory effects were variable, context-dependent, and strain-specific.

Chimpanzee CD4 Polymorphisms Interfere with Env Binding by Altering Contact Residues at the CD4–Env Interface. Having identified protective CD4 alleles, we next sought to examine the breadth of this protection and the associated mechanism(s). Both R25- and R40-containing CD4 alleles inhibited primarily SIVcpzPts




Fig. 3. Chimpanzee CD4 polymorphisms govern SIVcpz Env-mediated cell entry. The infectivity of pseudoviruses carrying different SIVcpz Envs is shown for transiently transfected cells expressing human and chimpanzee CD4 alleles. The infectivity on human CD4-expressing cells is set to 100%. Bars represent the average of three independent transfections, each performed in triplicate, with standard deviations shown.

strains (Figs. 3 and 4), but CD4 genotyping of 128 chimpanzees from Gombe National Park identified two SIVcpzPts-infected individuals that were R25-heterozygous. Since the virus of one of these individuals (TAN1) has been molecularly cloned (44), we tested its Env in the CD4 transfection assay (Fig. 4A). This analysis showed that TAN1, in contrast to the other SIVcpzPts Envs, was able to utilize the R25 allele (Fig. 4A). Similarly, of five SIVcpzPts strains, four were resistant to the R40 inhibition, and all four were derived from chimpanzees that encoded at least one R40-containing allele (Fig. 4C). Thus, for both R25 and R40 polymorphisms, in vivo adaptation had generated SIVcpz strains that were capable of utilizing these CD4 variants.

To identify the mechanisms of inhibition mediated by R25 and R40, we mapped these CD4 residues onto an existing crystal structure of the human CD4 bound to HIV-1 gp120 (38). We then searched for Env amino acids that were in close proximity to these CD4 residues but differed between restricted and permissive SIVcpz strains (Fig. 4B and D). For the R25 polymorphism, we found that Env residue 474 (HXB2 reference sequence numbering) was negatively charged or neutral in all viruses that were able to utilize the QRNV allele, but positively charged in SIVcpz strains that were unable to utilize this allele (Fig. 4B). This finding suggested that the CD4 R25 repulsed positively charged Env amino acids at position 474, thus destabilizing the Env–CD4 interaction. Since the permissive TAN1 strain encoded a valine at this position, we mutagenized a restricted Env (TAN2) by replacing its lysine with a valine (K474V). This single amino acid substitution was sufficient to render the TAN2 Env infectious for cells expressing the QRNV allele without altering its ability to utilize the QQNVP allele (Fig. 4E). Similarly, residue 455 tended to be negatively charged in Envs that could use R40-containing CD4 alleles, but neutral in Envs that were blocked by this allele (Fig. 4D). In this instance, the different orientation of the R40 side chain was incompatible with an interaction with Env residue T283, the contact residue for CD4 Q40. However, this loss was predicted to be potentially offset by the formation of long-range salt bridges between CD4 R40 and a negatively charged residue at Env position 455. In line with this prediction, replacing a threonine at position 455 with an aspartic acid (T455D) in the restricted MB897 Env was sufficient to restore its infectivity for QRNV-expressing cells without altering its ability to utilize the QQNVP allele (Fig. 4E).

To examine the effect of the T455D mutation in the context of a replication-competent virus, we introduced this change into the MB897 infectious molecular clone and tested its infectivity in CD4⁺ T cells from a chimpanzee (Chip) that was heterozygous for the QRNV and QQNVT alleles (Fig. 1). Remarkably, this single amino acid substitution rendered MB897 infectious in cells that were completely refractory to the WT virus (Fig. 4F), and the same results were obtained in CD4⁺ T cells from a chimpanzee that was heterozygous for QRKVT and QQNVT alleles (*SI Appendix, Fig. S7A*). Although Env amino acid 455 is unlikely the only residue impacted by the R40 substitution (the LB715 Env encodes a T at position 455 but is able to use the QRNV allele), it seems clear that changes in the charge of Env/CD4 contact residues represent one mechanism by which CD4 polymorphisms prevent Env-mediated cell entry. Of note, R25 and R40 blocked CD4/Env interaction by different means since Env mutations that restored infectivity for one of these CD4 alleles did not restore infectivity for the other (Fig. 4E).

Chimpanzee CD4 Polymorphisms Cause Glycan–Glycan Steric Hindrance. In contrast to the R25 and R40 alleles, the T68 polymorphism inhibited all SIVcpz Envs regardless of their baseline infectivity (Fig. 3). Since T68 creates a PNGS at position N66 in addition to the N32 that is present in all chimpanzee CD4 alleles, we asked whether these sites were indeed glycosylated. Immunoprecipitation of CD4 proteins from cells transfected with human and chimpanzee (QQNVP and QQNVT) alleles revealed differences in electrophoretic mobility consistent with glycan occupancy, which was confirmed by endoglycosidase H treatment (*SI Appendix, Fig. S8*). To determine whether these D1 domain glycans interfered




Fig. 4. SIVcpz cell entry is blocked by charged residues at the CD4-Env interface. (A and C) Percentage of cells expressing the indicated CD4 alleles that are infected by SIVcpz Env-containing pseudoviruses. Points connected by lines represent paired averages of three independent experiments, each performed in triplicate. The parentheses indicate the CD4 genotype (amino acid at positions 25 in A and position 40 in C) of the naturally infected chimpanzee from which the respective SIVcpz Env was derived. (B and D) Modeling of chimpanzee CD4 residues 25 (B) and 40 (D) onto the crystal structure of the HIV-1 gp120 (yellow) bound to human CD4 (green). Polymorphic CD4 residues are shown in dark blue (Q) and red (R), respectively. Env residues in proximity to these polymorphic sites are highlighted. Partial Env protein alignments for the tested SIVcpz strains are shown, with the residue predicted to interact with the polymorphic CD4 residue highlighted (blue for Envs that can use both Q and R residues, red for Envs that are inhibited by the R residue). (E) Infectivity of WT (MB897, TAN2) and mutant (MB897 T455D, TAN2 K474V) SIVcpz Envs on cells expressing the indicated chimpanzee CD4 alleles. Circles represent average infectivity values from three independent experiments, each performed in triplicate, with mean and standard deviation shown. Significant differences are indicated (** $P < 0.01$, unpaired t test). (F) Replication potential of wild-type (wt) and mutant (T455D) MB897 and wild-type MT145 in chimpanzee CD4⁺ T cells heterozygous for QRNV and QQNV alleles. Viral replication was monitored in culture supernatants by determining reverse transcriptase (RT) activity.

with glycans on the various SIVcpz Envs, we modeled their position in the crystal structure of the human CD4 bound to HIV-1 gp120 (38). This analysis identified three glycans in the MB897 Env that were predicted to clash with glycans in the chimpanzee CD4 protein (Fig. 5A). Env glycan N460 was predicted to clash with CD4 glycan N32 while Env glycans N295 and N446 were predicted to clash with CD4 glycan N66, albeit on adjacent Env protomers. Interestingly, no substantial glycan-glycan clashes were predicted for the Envs of MT145 and TAN2, both of which were able to replicate efficiently in CD4⁺ T cells from QQNV-homozygous chimpanzees (Fig. 1D).

To examine whether removal of the clashing glycans in the MB897 Env would increase its infectivity, we changed the asparagine residues at positions 295, 446, and 460 to glutamines and then tested these mutants, alone and in combination, in the transient CD4 transfection assay (Fig. 5B). Interestingly, the N460Q and the triple mutant increased the infectivity of the MB897 Env in both QRNV- and QQNV-expressing cells (Fig. 5B). In contrast, removal of N295 and/or N446 had little effect in the context of

either allele (Fig. 5B). Introduction of these same mutations into the MB897 infectious molecular clone were consistent with these results. Compared with WT MB897, both the N460Q and the triple mutant grew faster and to higher titers in CD4⁺ T cells from a QRNV/QRNV-heterozygous chimpanzee (Fig. 5C). The N460Q mutant also replicated in CD4⁺ T cells from one, but not all, QRNV-homozygous chimpanzees (Fig. 5D and E) while N295Q and/or N446Q mutants again had no effect. Thus, removal of an Env glycan predicted to clash with the conserved N32 increased the infectivity of the MB897 strain, both in transient transfection and replication studies, albeit not to the level of other QQNV-permissive SIVcpz strains, such as MT145. Removal of the other two glycans failed to restore infectivity, although this was not due to a fitness cost, since all mutants replicated to the same extent in human CD4⁺ T cells (SI Appendix, Fig. S7B). Thus, in silico modeling of the CD4 and Env glycan shields did not fully recapitulate the extent of their interactions.

Chimpanzee CD4 Polymorphisms Protect Against SIVs Infecting Old World Monkeys. To test whether the inhibitory effect of the chimpanzee CD4 polymorphisms extended to more diverse SIVs, we cloned env genes from several SIV lineages into expression vectors, generated pseudoviruses, and tested their functional integrity in TZM-bl cells. Infectious Envs were then tested for CD4 dependence, and only those that required CD4 for cell entry




Fig. 5. Steric hindrance between CD4- and SIVcpz Env-encoded glycans. (A) A model of two SIVcpz Envs (Top, MB897; Bottom, MT145) in complex with the chimpanzee CD4 QQNV variant (containing both N32 and N66 glycans) is shown. Env residues are shown in purple, Env glycans in green, and CD4 glycans in red. (B) Infectivity of WT and mutant MB897 Envs lacking the indicated glycans in cells expressing different CD4 alleles (parentheses indicate the number of D1 domain glycans). Asterisks denote significant enhancement of the mutant Envs relative to the MB897 WT (orange) for that particular allele. (C-E) Replication of wild-type and mutant MB897 viruses in CD4⁺ T cells from one heterozygous chimpanzee encoding QRNV and QQNV alleles (C) and two homozygous chimpanzees encoding the QQNV allele (D and E).

were further analyzed. Using the transient CD4 transfection assay, we identified nine Envs from SIVs infecting mustached monkeys (*Cercopithecus cephus*), l'Hoest's monkeys (*Cercopithecus lhoesti*), western red colobus (*Procolobus badius*), red-tailed monkeys (*Cercopithecus ascanius*), sooty mangabeys (*Cercocebus atys*), and African green monkeys (*Chlorocebus tantalus*) that mediated entry into cells expressing the human CD4 (Fig. 6A). However, when these same Envs were tested in cells expressing the chimpanzee QQNVP allele, the great majority exhibited markedly reduced infectivity, with some of them inhibited even more in cells expressing the chimpanzee QQNVT allele (SI Appendix, Fig. S6F). To examine possible mechanisms, we mutagenized the conserved N32 glycan in both the QQNVP and QQNVT alleles. Changing the asparagine at position 32 to a glutamine (N32Q) in the QQNVP allele enhanced the infectivity of most SIV Envs, suggesting that their inhibition was primarily glycan-mediated (SI Appendix, Fig. S6F). However, the same mutation in the QQNVT allele did not restore Env infectivity, suggesting that one glycan in the D1 domain is sufficient to exert inhibition (Fig. 6B and SI Appendix, Fig. S6F). For six SIV Envs that retained infectivity for the chimpanzee QQNVP allele, we also tested the remaining CD4 polymorphisms (Fig. 6C). Both the N52K and V55I polymorphisms inhibited Envs of the SIVsmm lineage but had little effect on the other SIV Envs, except for SIVagm, which was enhanced by the K52 substitution (SI Appendix, Fig. S6G). Since the African green monkey CD4 encodes an R at position 52, this substitution likely generated a chimpanzee CD4 allele that resembled the cognate SIVagm receptor more closely. The R25 substitution inhibited one SIVagm and one SIVsmm Env, but none of the other SIV Envs (SI Appendix, Fig. S6G). The most pronounced protective effect was again observed for the R40 substitution, which reduced cell entry of all SIV Envs by ~10-fold, except for the Env of SIVasc (SI Appendix, Fig. S6G). Thus, like for SIVcpz strains, CD4 polymorphism-mediated inhibition of SIV cell entry was strain-specific and context-dependent.

CD4 Receptor Diversity Protects Wild Chimpanzees from SIVcpz Infection. Finally, we asked whether the various chimpanzee CD4 alleles influenced SIVcpz acquisition in vivo. To address this, we selected chimpanzee communities at two field sites where CD4 diversity could be analyzed in the context of high SIVcpz prevalence rates (SI Appendix, Table S3). One included Gombe National Park, where members of the Mitumba, Kasekela, and Kalande communities have been monitored for SIVcpz for two decades and where the negative impact of this infection on chimpanzee health was first demonstrated (27, 28). The other included the Lobéké (LB) and Mambélé (MB) area in southeastern Cameroon where chimpanzees harbor the closest relatives of HIV-1 group M at high prevalence rates (22). Using logistic regression to examine the effect of CD4 substitutions on SIVcpz infection relative to the ancestral CD4 allele, we found a suggestion of a protective effect for the R25 polymorphism in the Gombe population although this did not reach statistical significance (Fig. 7A). The 70 chimpanzees from the Lobéké (LB) and Mambélé (MB) area lacked the R25 polymorphism but encoded CD4 alleles with other substitutions in exon 2 and exon 3. When these were analyzed, none of them reached statistical significance although there was a trend for R40 and K52 to be associated with lower, and for I55 to be associated with higher, SIVcpz infection rates (Fig. 7B). Surprisingly, the T68 substitution did not appear to have a detectable effect. However, since only 4 of 46 individuals encoded T68 in the absence of K52, the impact of these two substitutions could not be differentiated. Interestingly, when the LB/MB data were analyzed at the whole exon level, the KVT allele was associated with 3.4-fold lower odds of being infected ($P = 0.03$, 95% CI: 1.07- to 10.8-fold) (Fig. 7). These data thus suggest that K52 (alone or in combination with T68) and, possibly, also R25 protect wild chimpanzees against infection by locally circulating SIVcpz strains although definitive conclusions must await more extensive sampling of wild populations.




Fig. 6. Chimpanzee CD4 polymorphisms protect against monkey SIVs. (A) Percent infectivity of Env-carrying pseudoviruses from diverse SIV lineages (color-coded) of cells expressing the indicated CD4 alleles (parentheses indicate the number of D1 domain PNGSs). Bars represent the average of three independent experiments, each performed in triplicate. Infectivity values are shown relative to the human CD4, which was set to 100%. Asterisks indicate statistically significant differences between the chimpanzee QQNVP and the human CD4, as well as between the chimpanzee QQNVP and QQNVT alleles (SI Appendix, Fig. S6). (B) Effect of the N32 glycan on SIV Env infectivity. Average infectivity values are shown for each Env tested against CD4 alleles with intact or mutated N32. Solid lines indicate statistical significance (SI Appendix, Fig. S6). (C) Effect of CD4 polymorphisms on SIV Env infectivity. Percent infectivity values are compared between chimpanzee CD4 allele pairs that differ at one polymorphic site (highlighted in red). Solid lines indicate statistical significance (SI Appendix, Fig. S6).

Discussion

Pathogenic SIVs have long been assumed to be the driving force behind the positive selection of primate CD4, but direct evidence has been lacking (39, 40). Here, we show that wild chimpanzees encode nine different CD4 variants, all of which are the result of nonsynonymous SNPs in the D1 domain that binds the HIV/SIV Env trimer (Figs. 1 and 2). Testing their impact on virus infection, we found that these polymorphisms inhibited cell entry of SIVcpz, as well as more distantly related SIVs, albeit in a strain-specific and context-dependent manner (Figs. 3 and 7). The most striking effects were seen for amino acid substitutions at positions 25, 40, and 68 of the mature CD4 protein in codons not previously identified to be under positive selection (39, 40). In silico modeling and site-directed mutagenesis identified charge changes at the Env/CD4 interface (Fig. 4) as well as clashes between Env- and CD4-encoded glycans (Fig. 6) as mechanisms of cell entry inhibition. The finding of polymorphisms in the chimpanzee CD4 that alter its function as a virus receptor, but do not appear to interfere with its MHC class II binding ability, strongly suggest that they evolved in response to SIV-mediated selection.

Although SIVcpz is pathogenic in chimpanzees (26–28), it is unlikely that it is the only SIV that has exerted pressure on the chimpanzee CD4 protein. *P. t. verus* and *P. t. ellioti* do not harbor SIVcpz, which suggested a more recent introduction of this virus, after the split of these subspecies from *P. t. troglodytes* and *P. t. schweinfurthii*. Indeed, the structure of the SIVcpz genome represents a complex mosaic, which resulted from the cross-species transmission and recombination of SIV lineages infecting red-capped mangabeys (*Cercocebus torquatus*) and certain *Cercopithecus* monkey species (10). Since the ranges of these species overlap that of *P. t. troglodytes* apes, it seemed likely that SIVcpz




Fig. 7. Effect of CD4 polymorphisms on SIVcpz infection rates in wild chimpanzees. A logistic regression was used to estimate the effects of CD4 polymorphisms on SIVcpz infection in wild-living chimpanzees from (A) Gombe and (B) Lobéké/Mambélé. Dots indicate the estimated effect of the presence of the given residue (Left) or allele (Right) relative to the ancestral state, with horizontal lines indicating the 95% confidence intervals (substitutions/alleles that could not be estimated by the model due to insufficient variation in the population are not shown). Dashed vertical lines mark a fold change of 1, indicating no predicted change in SIVcpz infection rate relative to the ancestral state.

first emerged in west central Africa and subsequently spread eastward (16). However, the fact that *P. t. ellioti*, *P. t. troglodytes*, and *P. t. schweinfurthii* share several CD4 alleles indicates that CD4 diversification preceded their divergence (Fig. 2). Thus, either current-day SIVcpz is much older than previously thought and selected CD4 variants in ancestral chimpanzees before becoming extinct in *P. t. verus* and *P. t. ellioti*, or chimpanzees have been episodically infected with different SIVs throughout their evolutionary history, which placed pressure on their CD4. Still another possibility is that some, or all, of the CD4 polymorphisms were selected by unrelated pathogen(s) (53, 54). However, others have independently implicated an ancient SIV infection to explain the skewed MHC class I repertoires of chimpanzees and bonobos, which include allotypes that resemble AIDS-protective human HLA alleles (55). Thus, there are several lines of evidence to suggest that different SIVs, both extant and extinct, have shaped the evolution of the chimpanzee CD4.

The finding of only a single CD4 allele in western chimpanzees is intriguing. This could indicate that the selection pressure that maintains CD4 diversity in the other subspecies has been removed although these apes are almost certainly exposed to a similar variety of SIVs from various sympatric monkey species. Alternatively, exposure to new SIV(s) as the ancestors of *P. t. verus* migrated westward may have led to a selective sweep fixing the one CD4 allele although there is no obvious trough of genetic diversity surrounding the CD4 locus (SI Appendix, Fig. S10). This particular allele is now extremely rare among the other three subspecies, but its fixation in the western subspecies, either by selection or drift, suggests that it was more common in the past.

Current data indicate that the SIV/HIV Env trimer must engage at least two different CD4 molecules before it can trigger fusion and cell entry (56–58). Although the regulation of CD4 expression in heterozygous chimpanzees is unknown, it is likely that CD4+ T cells express both CD4 alleles (59–61). If two different CD4 variants are expressed on the same target cell, then multiple permutations of Env trimer binding are possible. Depending on the stoichiometry and kinetics of engagement, interaction of Env protomers with CD4 molecules that vary in their binding affinities may result in less efficient cell entry than interaction with CD4 molecules that do not exhibit this difference. It is also possible that in vivo adaptation of a virus to one set of CD4 alleles decreases its fitness to infect chimpanzees that encode a different set of CD4 alleles. For example, adaptation of SIVcpz strains to CD4 alleles that encode two D1 domain glycans through modification of their Env glycan shield may render them more vulnerable to host immune responses. The loss of Env glycan shielding, as seen in the promiscuous MT145 strain (Fig. 5A), is known to

generate epitopes that are targeted by strain-specific neutralizing antibodies, which select for viral escape variants in which the glycan holes are filled (62). Thus, the requirement to interact with different CD4 alleles may curb SIVcpz transmission and/or reduce viral replication in infected individuals. Interestingly, of three captive chimpanzees that were infected with the same SIVcpz strain (ANT) at the same time over 20 y ago, only the two that were homozygous for the QQNVT allele developed high viral loads and progressed to AIDS (30, 63, 64). The third individual, who is heterozygous for QQNVT and QQNVP alleles, exhibited much lower viral loads and has remained healthy (SI Appendix, Table S4). These findings suggest that CD4 variants are maintained in wild chimpanzee populations because they confer a heterozygote advantage.

One CD4 polymorphism that potentially inhibits SIVcpz strains *in vitro* is the R25 substitution (Fig. 3). Despite screening over 500 chimpanzees, this polymorphism was found only in chimpanzees from Gombe National Park. The limited geographic distribution suggests that the RQNVP allele may have emerged relatively more recently although definitive conclusions require testing of additional communities. Since there was a trend for the RQNVP allele to be associated with lower SIVcpz infection rates (Fig. 7), we examined its distribution among the three Gombe communities. Interestingly, of 23 CD4-genotyped Kalande chimpanzees, 11 of whom were SIVcpz-positive, none carried the RQNVP allele. In contrast, of 75 and 30 Kasekela and Mitumba chimpanzees, 20% and 10% of whom were infected, respectively, 23 and 3 carried at least one RQNVP allele. Thus, one reason for the higher SIVcpz prevalence in the Kalande community, which has been linked to its catastrophic population decline (28), may be the absence of the protective RQNVP allele. Although it is unclear why the distribution of the RQNVP allele is so different between the otherwise interconnected Gombe communities, it will be important to determine whether its frequency can explain differences in SIVcpz prevalence rates that are particularly pronounced among *P. t. schweinfurthii* communities in the easternmost part of their range (21).

Humans acquired the ape precursors of HIV-1 by cross-species transmission on four independent occasions, resulting in groups M, N, O, and P (16). In contrast, SIVcpz appears to have arisen only once, despite frequent exposure of chimpanzees to SIVs (31). Here, we show that receptor glycosylation serves as a potent barrier to SIV cell entry. Both conserved (N32) and variable (N66) D1 domain glycans were shown to inhibit not only SIVcpz, but also other SIV strains (Fig. 6). While many additional SIV lineages remain to be analyzed, our data indicate that steric hindrance between cell entry receptor-encoded and virus surface protein-encoded glycans represents a mechanism of antiviral protection that has not previously been described. Indeed, glycosylation of the CD4 receptor is common among primates where PNGS are found at variable positions in the D1 domain (SI Appendix, Table S5). Moreover, all of these appear to be under positive selection within the primate lineage (SI Appendix, Fig. S9). Humans lack D1 domain glycans, which may explain their relative susceptibility to SIVcpz, SIVgor, and SIVsmm infections, which have crossed the species barrier on at least 12 occasions (16). Conversely, the presence of glycans on the chimpanzee CD4 must be one reason why chimpanzees are largely resistant to experimental HIV-1 infection. It will be interesting to examine the evolution of the Env glycan shield in HIV-1 strains that were able to establish a productive infection in chimpanzees after multiple rounds of *in vivo* adaptation (65).

The discovery of CD4-mediated protection has practical implications for AIDS vaccine development. We recently discovered that a subset of SIVcpz strains share unexpected antigenic cross-reactivity with HIV-1 in the functionally important V1V2 region of the Env trimer apex (45). This finding raised the question whether SIVcpz Envs, which are otherwise antigenically highly divergent from HIV-1, could serve to immunofocus B cell responses in humans to this critical epitope. Indeed, a minimally

modified Env of the SIVcpz strain MT145 was recently shown to display selective binding to HIV-1 V2-apex broadly neutralizing antibodies (bNabs) and their precursors, and to prime heterologous (tier 2) neutralizing antibody responses in V2 apex bNab precursor antibody-expressing knock-in mice (66). MT145 is the only SIVcpz strain that was able to replicate in CD4⁺ T cells of all chimpanzees (Fig. 1), at least in part because it lacks Env glycans predicted to clash with N32 and N66 in the chimpanzee CD4 (Fig. 5A). Indeed, cryo-EM analysis of the MT145 Env trimer revealed that its structure is remarkably similar to that of the HIV-1 Env, except for a shift in the arrangement of its glycans (66). It thus appears that MT145 has evolved to accommodate the chimpanzee CD4-mediated cell entry block by rearranging its Env glycan shield. However, the absence of the N460 glycan exposes a long V5 loop (Fig. 5A), which has the potential to induce unwanted (off-target) antibody responses. Since there are other SIVcpz Envs that contain the cross-reactive V2 apex epitope but lack the long unshielded V5 loop (45), they may be more suitable components of an immunofocusing strategy to elicit V2 apex bNab responses. As vaccines including SIVcpz Env immunogens are moving toward human clinical testing, understanding the impact of chimpanzee CD4 diversification on their structure and function will inform AIDS immunogen design.

Methods

Vectors. The construction and biological characterization of the SIVcpz IMCs have previously been reported (21, 44–47). Insertion of a GFP-internal ribosome entry site (IRES) cassette between the *env* and *nef* genes of the MB897 IMC generated a replication-competent SIVcpz-GFP reporter virus, which was further modified by inserting a frameshift at position 6,493 in the *env* gene for pseudotyping studies. WT or codon-optimized SIVcpz and SIV *env* genes were cloned into pCDNA3.1. Full-length chimpanzee and human CD4 coding sequences, as well as the chimpanzee CCR5 gene, were cloned into pMSCVPuro (Takara Bio Inc.).

Virus Stocks. Viral stocks were generated by transfecting of 293T cells with SIVcpz IMCs and by testing the culture supernatants for infectivity on TZM-bl cells. Pseudovirus stocks were generated by cotransfecting the MB897ΔEnv-GFP backbone with WT or codon-optimized SIVcpz and SIV Env expression plasmids and also titered on TZM-bl cells. The replication-competent MB897-GFP IMC was used for VSV-G complementation studies.

CD4⁺ T Cell Cultures. Blood samples were obtained from captive chimpanzees housed at the Yerkes National Primate Research Center, the Southwest National Primate Research Center, and the New Iberia Research Center during their annual health examination. Only leftover material was used, which was approved by the respective Institutional Animal Care and Use Committees. Human blood was purchased (ZenBio, Inc). Chimpanzee and human CD4⁺ T cells were isolated, activated, and infected overnight at a multiplicity of infection (MOI) of 0.1 as described (44, 67). Virus replication was assessed by monitoring reverse transcriptase activity (Sigma-Aldrich) or the presence of p24 core protein (AlphaLISA Detection Kit; Perkin-Elmer) in culture supernatants.

CD4 and CCR5 Genotyping. To determine the CD4 and CCR5 genotype of captive chimpanzees, total RNA was extracted from activated CD4⁺ T cells and reverse transcribed using SuperScript III (Thermo Fisher) gene-specific primers. To preclude PCR artifacts, cDNA was endpoint diluted (48) to amplify single mRNA templates (see *SI Appendix, SI Materials and Methods* for primer sequences and amplification conditions). Multiple amplicons were MiSeq sequenced to determine the CCR5 and CD4 genotype (*SI Appendix, Table S2*). To CD4 genotype wild chimpanzee populations, samples were selected from existing specimen banks (4, 21, 22, 27, 28, 49, 50) based on geographic origin, subspecies association, SIVcpz infection status, and host mitochondrial and microsatellite information, as well as sample availability and quality (*SI Appendix, Tables S3 and S6* for available sample information). CD4 exon 2 (247 bp) and exon 3 (222 bp) regions were amplified using primers in adjacent introns (*SI Appendix, SI Materials and Methods*). Amplicons were MiSeq sequenced without fragmentation to ensure linkage of variable sites (68, 69). Homozygous loci were amplified at least eight times to exclude allelic dropout (*SI Appendix, Table S3*).

Transient CD4 Transfection Assay. To determine the ability of SIVcpz and SIV Envs to utilize different CD4 alleles for cell entry, we developed a single round infection assay. Briefly, 293T cells were cotransfected with human and chimpanzee CD4 and chimpanzee CCR5 expression plasmids, cultured for 48 h, and then plated in 96-well plates at a density of 2×10^4 cells per well. After 24 h, transfected cells were infected with 5,000 infectious units (IUs) of SIV Env bearing pseudovirus by spinoculation, cultured for 48 h, and then analyzed for GFP expression by flow cytometry (*SI Appendix, Fig. S4*). CD4 and CCR5 expression levels were determined at the time of infection using receptor-specific antibodies, and the percentage of infected cells was calculated by dividing the number of GFP-expressing cells by the number of CD4- and CCR5-expressing cells for each transfected cell population. All Envs were analyzed in triplicate on three independent occasions.

Modeling Glycosylated SIVcpz Env Trimer and CD4. To obtain models of SIVcpz trimers and CD4 variants, the structure of HIV-1 clade G $\times 1193.c1$ SOSIP.665 (PDB ID code 5FYJ) protein (70) and the human CD4 (PDB ID code 1GC1) protein (38) were used as templates in SwissModel (71). N-linked Man-5 glycans were added to both SIVcpz trimer and CD4 models in silico using the in-house program Glycosylator at all possible glycosylation sequons. Complexes of modeled glycosylated CD4 and SIVcpz trimers were built by structural alignment of gp120 from 1GC1 to the corresponding residues in the trimeric SIVcpz gp120. Glycan-glycan spatial overlaps were evaluated by visual inspection of multiple glycan rotamers.

Statistical Analyses. To assess the effects of CD4 polymorphisms on SIVcpz- and SIV Env-mediated cell entry in vitro, we used a hierarchical Bayesian model (*SI Appendix*). For each pair of CD4 alleles, the fold change in infectivity for the various Envs, as well as an overall effect estimate, was modeled using Stan (72). To assess the effects of CD4 polymorphisms on SIVcpz infection in vivo, we selected two different populations of eastern (Gombe) and central (Lobéké/Mambélé area) chimpanzees that were infected at high SIVcpz prevalence rates. We then performed a logistic regression of SIVcpz status on sets of indicator variables that specified whether a chimpanzee possessed a given CD4 substitution or allelic variant, while setting the ancestral state as the background. This analysis tested whether the presence of a given substitution or allele within a community positively or negatively associated with SIVcpz infection relative to the ancestral (g) QQNVP genotype although the model did not account for zygosity or synergistic effects between polymorphisms.

ACKNOWLEDGMENTS. We thank the staff of the Yerkes and Southwest National Primate Research Centers, as well as Jane Fontenot, Melany Musso, and Francois Villinger (New Iberia Research Center) for providing leftover blood samples from captive chimpanzees; the staff of the Sanaga-Yong Rescue Center, the Chimpanzee Conservation Center (CCC), and the Tchimpounga Chimpanzee Rehabilitation Centre for preserving leftover blood samples from rescued apes; the staff of project PRESICA, the World Wildlife Fund for Nature (WWF)/Democratic Republic of the Congo (DRC), and researchers at the Parc National de la Lopé for fieldwork in Cameroon, the DRC, and Gabon, respectively; the Jane Goodall Institute field staff at the Gombe Stream Research Centre, as well as field assistants from the Greater Mahale Ecosystem Research and Conservation Project (GMERC) for collecting chimpanzee fecal samples in Tanzania; the Gashaka Primate Project for collecting chimpanzee fecal samples in Nigeria; the Ministries of Environment and Forests and Research, Office Ivoirien des Parcs et Réserves, Taï National Park, and the Swiss Centre for Scientific Research for permission to perform studies in Côte d'Ivoire; the Cameroonian Ministries of Health, Forestry and Wildlife, and Scientific Research and Innovation for permission to collect samples in Cameroon; the governments of Guinea, Guinea-Bissau, Nigeria, and Gabon for permission to collect fecal samples from wild chimpanzees; the Water and Forest Ministry for permission to collect samples in the Central African Republic; the Ministry of Forest Economy and Sustainable Development for permission to collect samples in the Republic of Congo; the Ministry of Scientific Research and Technology, the Department of Ecology and Management of Plant and Animal Resources of the University of Kisangani, the Ministries of Health and Environment and the National Ethics Committee for permission to collect samples in the DRC; and the Tanzania Commission for Science and Technology (COSTECH), the Tanzania Wildlife Research Institute (TAWIRI), and the Tanzania National Parks Authority (TANAPA) for their support and permission to conduct research in Gombe and the Greater Mahale Ecosystem (GME). This work was supported in part by National Institutes of Health Grants R01 AI120810, R01 AI091595, R37 AI050529, UM1 AI100645, UM1 AI126620, and P30 AI045008 (to B.H.H.); Yerkes National Primate Research Center Grant P51 RR-000165; Southwest National Primate Research Center Grants P51 RR013986 and P51 OD011133; Agence Nationale de Recherche pour le SIDA Grant ANRS 12325 (to M.P.); and Canadian Institutes of Health Research (CIHR) Foundation Grant 352417 and Canada Research Chair CRC RCHS0235 (to A.F.). R.M.R. is supported by Training Grant T32 AI 007632. S.D. is supported by a Fonds de Recherche Santé Québec (FRQS) postdoctoral fellowship.

1. Peeters M, Ma D, Liegeois F, Apetrei C (2014) Simian immunodeficiency virus infections in the wild. *Natural Hosts of SIV*, eds Ansari A, Silvestri G (Elsevier, New York), pp 37–67.
2. Aghokeng AF, et al. (2010) Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. *Infect Genet Evol* 10:386–396.
3. Courgnaud V, et al. (2002) Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (*Cercopithecus nictitans*) provides new insights into simian/human immunodeficiency virus phylogeny. *J Virol* 76: 8298–8309.
4. Santiago ML, et al. (2003) Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees (*Pan troglodytes schweinfurthii*). *J Virol* 77: 7545–7562.
5. Van Heuverswyn F, et al. (2006) Human immunodeficiency viruses: SIV infection in wild gorillas. *Nature* 444:164.
6. Compton AA, Malik HS, Eberman M (2013) Host gene evolution traces the evolutionary history of ancient primate lentiviruses. *Philos Trans R Soc Lond B Biol Sci* 368: 20120496.
7. Etienne L, et al. (2015) The role of the antiviral APOBEC3 gene family in protecting chimpanzees against lentiviruses from monkeys. *PLoS Pathog* 11:e1005149.
8. McCarthy KR, Kirmaier A, Autissier P, Johnson WE (2015) Evolutionary and functional analysis of old world primate TRIM5 reveals the ancient emergence of primate lentiviruses and convergent evolution targeting a conserved capsid interface. *PLoS Pathog* 11:e1005085.
9. Aghokeng AF, et al. (2007) Full-length sequence analysis of SIVmus in wild populations of mustached monkeys (*Cercopithecus cephus*) from Cameroon provides evidence for two co-circulating SIVmus lineages. *Virology* 360:407–418.
10. Bailes E, et al. (2003) Hybrid origin of SIV in chimpanzees. *Science* 300:1713.
11. Kuhmann SE, et al. (2001) Frequent substitution polymorphisms in African green monkey CCR5 cluster at critical sites for infections by simian immunodeficiency virus SIVagm, implying ancient virus-host coevolution. *J Virol* 75:8449–8460.
12. Souquière S, et al. (2001) Wild Mandrillus sphinx are carriers of two types of lentivirus. *J Virol* 75:7086–7096.
13. Worobey M, et al. (2010) Island biogeography reveals the deep history of SIV. *Science* 329:1487.
14. Pandrea I, Apetrei C (2010) Where the wild things are: Pathogenesis of SIV infection in African nonhuman primate hosts. *Curr HIV/AIDS Rep* 7:28–36.
15. Klatt NR, Silvestri G, Hirsch V (2012) Nonpathogenic simian immunodeficiency virus infections. *Cold Spring Harb Perspect Med* 2:a007153.
16. Sharp PM, Hahn BH (2011) Origins of HIV and the AIDS pandemic. *Cold Spring Harb Perspect Med* 1:a006841.
17. Pandrea I, et al. (2007) Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. *Blood* 109:1069–1076.
18. Riddick NE, et al. (2010) A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. *PLoS Pathog* 6:e1001064.
19. Cartwright EK, et al. (2014) Divergent CD4+ T memory stem cell dynamics in pathogenic and nonpathogenic simian immunodeficiency virus infections. *J Immunol* 192: 4666–4673.
20. Locatelli S, et al. (2016) Why are Nigeria-Cameroon chimpanzees (*Pan troglodytes ellioti*) free of SIVcpz infection? *PLoS One* 11:e0160788.
21. Li Y, et al. (2012) Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir. *J Virol* 86:10776–10791.
22. Keele BF, et al. (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. *Science* 313:523–526.
23. Takehisa J, et al. (2009) Origin and biology of simian immunodeficiency virus in wild-living western gorillas. *J Virol* 83:1635–1648.
24. D'arc M, et al. (2015) Origin of the HIV-1 group O epidemic in western lowland gorillas. *Proc Natl Acad Sci USA* 112:E1343–E1352.
25. Plantier JC, et al. (2009) A new human immunodeficiency virus derived from gorillas. *Nat Med* 15:871–872.
26. Etienne L, et al. (2011) Characterization of a new simian immunodeficiency virus strain in a naturally infected *Pan troglodytes troglodytes* chimpanzee with AIDS related symptoms. *Retrovirology* 8:4.
27. Keele BF, et al. (2009) Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. *Nature* 460:515–519.
28. Rudicell RS, et al. (2010) Impact of simian immunodeficiency virus infection on chimpanzee population dynamics. *PLoS Pathog* 6:e1001116.
29. Corbet S, et al. (2000) Env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. *J Virol* 74:529–534.
30. Barbian HJ, et al. (2017) Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. *Retrovirology* 14:35.
31. Newton-Fisher NE (2007) Chimpanzee hunting behavior. *Handbook of Paleoanthropology* (Springer, Berlin), pp 1295–1320.
32. Meyerson NR, Warren CJ, Vieira DASA, Diaz-Griffero F, Sawyer SL (2018) Species-specific vulnerability of RanBP2 shaped the evolution of SIV as it transmitted in African apes. *PLoS Pathog* 14:e1006906.
33. Gonder MK, et al. (2011) Evidence from Cameroon reveals differences in the genetic structure and histories of chimpanzee populations. *Proc Natl Acad Sci USA* 108: 4766–4771.
34. Janeway CA, Jr (1992) The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. *Annu Rev Immunol* 10:645–674.
35. Jönsson P, et al. (2016) Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions. *Proc Natl Acad Sci USA* 113:5682–5687.
36. Yin Y, Wang XX, Mariuzza RA (2012) Crystal structure of a complete ternary complex of T-cell receptor, peptide-MHC, and CD4. *Proc Natl Acad Sci USA* 109:5405–5410.
37. Clayton LK, Sieh M, Pious DA, Reinherz EL (1989) Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. *Nature* 339:548–551.
38. Kwong PD, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature* 393:648–659.
39. Meyerson NR, et al. (2014) Positive selection of primate genes that promote HIV-1 replication. *Virology* 454–455:291–298.
40. Zhang ZD, Weinstock G, Gerstein M (2008) Rapid evolution by positive Darwinian selection in T-cell antigen CD4 in primates. *J Mol Evol* 66:446–456.
41. Fomsgaard A, Hirsch VM, Johnson PR (1992) Cloning and sequences of primate CD4 molecules: Diversity of the cellular receptor for simian immunodeficiency virus/human immunodeficiency virus. *Eur J Immunol* 22:2973–2981.
42. Hvilson C, et al. (2008) Genetic subspecies diversity of the chimpanzee CD4 virus-receptor gene. *Genomics* 92:322–328.
43. Wertheim JO, Worobey M (2007) A challenge to the ancient origin of SIVagm based on African green monkey mitochondrial genomes. *PLoS Pathog* 3:e95.
44. Takehisa J, et al. (2007) Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees. *J Virol* 81: 7463–7475.
45. Barbian HJ, et al. (2015) Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. *MBio* 6:e00296-15.
46. Bibollet-Ruche F, et al. (2004) Complete genome analysis of one of the earliest SIVcpzPtt strains from Gabon (SIVcpzGAB2). *AIDS Res Hum Retroviruses* 20:1377–1381.
47. Bibollet-Ruche F, et al. (2012) Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation. *J Clin Invest* 122:1644–1652.
48. Salazar-Gonzalez JF, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. *J Virol* 82:3952–3970.
49. Liu W, et al. (2010) Origin of the human malaria parasite *Plasmodium falciparum* in gorillas. *Nature* 467:420–425.
50. Liu W, et al. (2014) African origin of the malaria parasite *Plasmodium vivax*. *Nat Commun* 5:3346.
51. Prado-Martinez J, et al. (2013) Great ape genetic diversity and population history. *Nature* 499:471–475.
52. Nei M (1973) Analysis of gene diversity in subdivided populations. *Proc Natl Acad Sci USA* 70:3321–3323.
53. Lavergne A, et al. (2014) African great apes are naturally infected with roseoloviruses closely related to human herpesvirus 7. *J Virol* 88:13212–13220.
54. Lusso P, et al. (1994) CD4 is a critical component of the receptor for human herpesvirus 7: Interference with human immunodeficiency virus. *Proc Natl Acad Sci USA* 91: 3872–3876.
55. de Groot NG, Heijmans CMC, Bontrop RE (2017) AIDS in chimpanzees: The role of MHC genes. *Immunogenetics* 69:499–509.
56. Ma X, et al. (2018) HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. *eLife* 7:e34271.
57. Salzwedel K, Berger EA (2009) Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: A general property of the functional trimer. *Retrovirology* 6:75.
58. Yang X, Kurtveva S, Ren X, Lee S, Sodroski J (2006) Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. *J Virol* 80:4388–4395.
59. Fuller TC, et al. (1984) Antigenic polymorphism of the T4 differentiation antigen expressed on human T helper/inducer lymphocytes. *Hum Immunol* 9:89–102.
60. Hughes EJ, Goddard EA, Bouic P, Beatty DW (1994) Flow cytometry analysis of OKT4 epitope deficiency in South African black children. *Clin Exp Immunol* 98: 526–531.
61. Morrison WI, Howard CJ, Hinson CJ, MacHugh ND, Sopp P (1994) Identification of three distinct allelic forms of bovine CD4. *Immunology* 83:589–594.
62. Wagh K, et al. (2018) Completeness of HIV-1 envelope glycan shield at transmission determines neutralization breadth. *Cell Rep* 25:893–908.e7.
63. Greenwood EJ, et al. (2015) Simian immunodeficiency virus infection of chimpanzees (*Pan troglodytes*) shares features of both pathogenic and non-pathogenic lentiviral infections. *PLoS Pathog* 11:e1005146.
64. Heeney JL, et al. (2006) Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficiency virus type 1 infection in chimpanzees. *J Virol* 80:7208–7218.
65. Novembre FJ, et al. (1997) Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. *J Virol* 71:4086–4091.
66. Andrabi R, et al. (2018) Chimpanzee SIV envelope trimer: Structure and deployment as an HIV vaccine template. [bioRxiv:1101/459164](https://doi.org/10.1101/459164). Preprint, posted November 1, 2018.
67. Decker JM, et al. (2009) Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes. *Virology* 394:109–118.
68. Barbian HJ, et al. (2018) CHIIMP: An automated high-throughput microsatellite genotyping platform reveals greater allelic diversity in wild chimpanzees. *Ecol Evol* 8: 7946–7963.
69. Liu W, et al. (2017) Wild bonobos host geographically restricted malaria parasites including a putative new *Laverania* species. *Nat Commun* 8:1635.
70. Stewart-Jones GB, et al. (2016) Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. *Cell* 165:813–826.
71. Waterhouse A, et al. (2018) SWISS-MODEL: Homology modelling of protein structures and complexes. *Nucleic Acids Res* 46:W296–W303.
72. Carpenter B, et al. (2017) Stan: A probabilistic programming language. *J Stat Softw* 76:1–32.